‘Outstanding Issues’ Near For Products Approaching EU Review End – Including Neulasta Biosimilar

 
• By Maureen Kenny

Ammtek, Pfizer, Portola and Roche are among the companies that are likely to find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are nearing the end of the review pathway. Questions are likely to be in store for the sponsor of a biosimilar version of pegfilgrastim.

EMA
It's a big week at the EMA • Source: Shutterstock

More from Europe

More from Geography